Curevac N.V. ((CVAC)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: CureVac N.V. is conducting a Phase I study titled Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC). The study aims to evaluate the safety and tolerability of the CVHNLC mRNA vaccine in combination with pembrolizumab, targeting metastatic squamous non-small-cell lung cancer. This research is significant as it explores innovative mRNA technology in cancer treatment.
Intervention/Treatment: The study tests the CV09070101 mRNA vaccine (CVHNLC) at various dose levels, combined with pembrolizumab, and later with chemotherapy agents carboplatin and paclitaxel. The goal is to find a safe and effective dose for treating sqNSCLC.
Study Design: This is an open-label, non-randomized, sequential intervention study. It focuses on treatment, with no masking involved, to assess the vaccine’s safety and tolerability in a real-world setting.
Study Timeline: The study was first submitted on July 9, 2025, with the same date marking its last update. It is currently not yet recruiting, indicating that patient enrollment has not started.
Market Implications: This study could impact CureVac’s stock performance positively if successful, as it represents a potential breakthrough in mRNA cancer therapies. Investors may watch closely, considering the competitive landscape with other companies exploring similar technologies.
The study is ongoing, and further details are available on the ClinicalTrials portal.